Table 1. Demographic and Clinical Characteristics of Patients With Cancer by PPI Use.
| Characteristic | Total patients, No. | Patients, No. (%) | P value | Multiparametric analysis, OR (95% CI) | |
|---|---|---|---|---|---|
| Do not use PPIsa | Use PPIs | ||||
| Total patients | 872 | 643 (73.7) | 229 (26.3) | NA | NA |
| Age, median (range), y | 63 (20-91) | 62 (20-91) | 66 (20-90) | <.001 | 1.02 (1.00-1.03) |
| Sex, No. (%) | |||||
| Female | 566 (64.9) | 425 (75.1) | 141 (24.9) | .25 | NA |
| Male | 306 (35.1) | 218 (71.2) | 88 (28.8) | ||
| Center | |||||
| Angers | 64 | 43 (67.2) | 21 (32.8) | <.001b | 2.10 (1.04-4.23) |
| Marseille | 55 | 29 (52.7) | 26 (47.3) | 3.49 (1.71-7.22) | |
| Nantes | 590 | 437 (74.0) | 153 (26.0) | 1.51 (0.94-2.53) | |
| Rennes | 163 | 134 (82.2) | 29 (17.8) | 1 [Reference] | |
| Eastern Cooperative Oncology Group performance status | |||||
| 0 | 407 | 332 (81.6) | 75 (18.4) | <.001b | 1 [Reference] |
| 1 | 367 | 248 (67.6) | 119 (32.4) | 1.92 (1.36-2.72) | |
| 2-3 | 75 | 45 (60.0) | 30 (40.0) | 2.51 (1.41-4.45) | |
| Unknown | 23 | 18 (78.3) | 5 (21.7) | NA | |
| Tumor extension | |||||
| Localized | 295 | 234 (79.3) | 61 (20.7) | .03b | NA |
| Locally advanced | 103 | 75 (72.8) | 28 (27.2) | ||
| Metastatic | 474 | 334 (70.5) | 140 (29.5) | ||
| Primary tumor | |||||
| Breast | 349 | 271 (77.7) | 78 (22.3) | .045b | NA |
| Gastrointestinal | 150 | 102 (68.0) | 48 (32.0) | ||
| Urologic | 96 | 66 (69.0) | 30 (31.0) | ||
| Thorax | 69 | 45 (65.2) | 24 (34.8) | ||
| Gynecologic | 58 | 40 (69.0) | 18 (31.0) | ||
| Brain | 47 | 36 (77.0) | 11 (23.0) | ||
| Hormonotherapy | 125 | 101 (80.8) | 24 (19.2) | .01 | 0.59 (0.37-0.90) |
Abbreviations: NA, not applicable; PPI, proton pump inhibitor.
a
Percentages are calculated across the row, not down the column.
b
The distributions between PPI users and nonusers were significantly different.